Skip to content
10-Q

Quarterly Report

Actinium Pharmaceuticals, Inc. ATNM

0001213900-24-036699

← back to feed
Filed
Apr 26, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 26, 2024 29.78M sh
Cash And Equivalents Q1 2024 · Mar 31, 2024 $84.06M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $76.68M
Current Liabilities Q1 2024 · Mar 31, 2024 $8.06M
Current Liabilities Q1 2024 · Dec 31, 2023 $8.49M
Total Liabilities Q1 2024 · Mar 31, 2024 $44.5M
Total Liabilities Q1 2024 · Dec 31, 2023 $45.07M
Current Assets Q1 2024 · Mar 31, 2024 $85.37M
Current Assets Q1 2024 · Dec 31, 2023 $78.26M
Total Assets Q1 2024 · Mar 31, 2024 $88.35M
Total Assets Q1 2024 · Dec 31, 2023 $81.45M
Shares Diluted Q1 2024 · Mar 31, 2023 25.7M sh
Capex Q1 2024 · Mar 31, 2023 $76K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$15.08M
Stockholders Equity Q1 2024 · Mar 31, 2023 $57.21M
Stockholders Equity Q1 2024 · Dec 31, 2022 $66.48M
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.43
Eps Basic Q1 2024 · Mar 31, 2023 −$0.43
Sga Expense Q1 2024 · Mar 31, 2023 $3.74M
Rd Expense Q1 2024 · Mar 31, 2023 $7.85M
Net Income Q1 2024 · Mar 31, 2023 −$11.04M
Operating Income Q1 2024 · Mar 31, 2023 −$11.58M